Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced the presentation of new data from the ongoing, real-world IMPACT-TD Registry. The findings demonstrate that treatment with AUSTEDO tablets or AUSTEDO XR extended-release tablets for tardive dyskinesia led to reductions in the severity of involuntary movements and improvements in patient-reported quality of life. The data were presented at the 2025 Neuroscience Education Institute Fall Congress, taking place November 6 – 9, 2025 in Colorado Springs, Colorado. The interim analysis of the IMPACT-TD Registry, a Phase 4 study, evaluated 27 adults with TD treated with AUSTEDO or AUSTEDO XR after a three-month period using IMPACT-TD PRO, a 30-question scale measuring patient-reported impact across 5 key areas. The study included patients with common comorbid psychiatric disorders, such as bipolar disorder (41%), anxiety disorder (37%), depression (26%), and schizophrenia (19%), reflecting a diverse, real-world patient population. Key results revealed: Patient-reported meaningful improvement after three months on AUSTEDO or AUSTEDO XR across several areas, including speech/communication (77%), eating (75%), psychosocial impact (65%), activities of daily living (59%), and sleep/pain (50%). At three months, the total motor score on the Abnormal Involuntary Movement Scale (AIMS) showed a mean decrease of -2.9, indicating a notable reduction in the severity of uncontrolled movements consistent with what was previously seen in pivotal trials. Most (85%) participants taking AUSTEDO or AUSTEDO XR in conjunction with their mental health medications reported that their underlying mental health condition remained stable or improved based on the Patient Global Impression of Severity (PGIS) scale. While Part A of the IMPACT-TD Registry demonstrated the broad impact TD has on individuals beyond physical movements, these initial findings from Part B reflect patient-reported improvements in everyday tasks like speaking, eating, and other activities of daily living as a result of movement reduction with AUSTEDO or AUSTEDO XR.
Meet Your ETF AI Analyst
Disclaimer & DisclosureReport an Issue
